Poliomyelitis, in short polio, is a crippling, potentially fatal and highly contagious illness caused by poliovirus with no cure.
Researchers using a century-old technique have determined the precise configuration of substances from hops that give beer its distinctive flavor. That could lead to formulation of new pharmaceuticals to treat diabetes, some cancers and other ailments.
Ever since discovering a decade ago that a gene altered in lung cancer regulated an enzyme used in therapies against diabetes, Reuben Shaw has wondered if drugs originally designed to treat metabolic diseases could also work against cancer.
Op-Ed by Nancy Klimas, M.D., one of the world’s leading researchers and clinicians in chronic fatigue syndrome/myalgic encepahalomyelitis (CFS/ME), is the director the NSU Institute for Neuro Immune Medicine
Clever intervention designed by a pharmacologist, a general practitioner and a biostatistician substantially reduced the prescribing of potentially dangerous medications. Reporters' conference call on January 23 at 9:30 EST The study’s three co-authors, Vittorio Maio, PharmD, MS, MSPH (a Jefferson pharmacology expert); Scott Keith, PhD (a Jefferson biostatistician); and Stefano Del Canale, MD, PhD (a practicing physician in Parma) will discuss their work. The dial-in telephone number is: +1-866-818-8556 Access Code: 5430707
Dr. Susan Holbeck, Ph.D., is a biologist in the Division of Cancer Treatment and Diagnosis at the National Cancer Institute. Her team spent two years testing all possible combinations of 100 cancer drugs currently approved by the FDA to see if any previously untested combinations are effective in certain cancers. 5,000 drug pairings were tested, totaling 300,000 experiments in all.
Psychiatrists who are exposed to conflict-of-interest (COI) policies during their residency are less likely to prescribe brand-name antidepressants after graduation than those who trained in residency programs without such policies, according to a new study by researchers from the Perelman School of Medicine at the University of Pennsylvania.
In the first study to examine discussion of drug side effects on Internet message boards, researchers from the Perelman School of Medicine at the University of Pennsylvania found that breast cancer survivors taking the commonly prescribed adjuvant therapy known as aromatase inhibitors (AIs) often detailed in these forums troublesome symptoms resulting from the drugs, and they were apt to report discontinuing the treatment or switching to a different drug in the same class.
Researchers have devised an apparently effective intervention to improve how physicians communicate to their patients five basic facts about a prescribed medication.
A rapid detection assay has been developed to Exserhilum rostratum, the fungus primarily responsible for 39 deaths among patients injected last year with a contaminated steroid medication. The test can be used both for patient samples and for detection of contamination in lots of medication.
Thomas Jefferson University researchers lead group that developed guidelines for early-stage development of radiosensitizers.
An experimental oral drug given to mice after a spinal cord injury was effective at improving limb movement after the injury, a new study shows.
A combination of the drugs pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer (ATC), according to a Mayo Clinic-led study published in the journal Science Translational Medicine. The two drugs together resulted in greater anti-cancer activity in ATC than either drug alone, says lead researcher Keith Bible, M.D., Ph.D., a Mayo Clinic oncologist.
People taking the blood pressure drugs called beta blockers may be less likely to have changes in the brain that can be signs of Alzheimer’s disease and other types of dementia, according to a study released today that will be presented at the American Academy of Neurology’s 65th Annual Meeting in San Diego, March 16 to 23, 2013.
Study shows patients who give their doctors high marks in communication more likely to fill prescriptions.
Researchers have discovered that adding lovastatin, a widely used cholesterol-lowering drug, to traditional antimalarial treatment decreases neuroinflammation and protects against cognitive impairment in a mouse model of cerebral malaria.
FDA approves ponatinib, third drug in four months; all clinical trials led by MD Anderson.
Researchers from Roswell Park Cancer Institute, the University of California at San Diego and CureFAKtor Pharmaceuticals have published the first evidence that inhibiting focal adhesion kinase with CFAK-Y15 can control the growth of glioblastoma tumors.
The Methodist Hospital in Houston and Dallas-based Remeditex Ventures LLC have entered into an exclusive agreement to develop an investigational drug for glioblastomas, the most malignant of all primary brain cancers. Current treatments only prolong survival for an average of five months.
InterveXion Therapeutics LLC and the University of Arkansas for Medical Sciences (UAMS) have successfully completed dosing in the first human safety study of a medication to help methamphetamine users fight their addictions.
Drug Czar Gil Kerlikowske is set to release new information about teen drug use on Wednesday. There are steps every parent can take to keep potentially dangerous medications out of the wrong hands.
An international study of ibrutinib in people with relapsed or refractory mantle cell lymphoma (MCL) continues to show unprecedented and durable results with few side effects.
A new study by NYU School of Medicine researchers suggests that an existing HIV drug called maraviroc could be a potential therapy for Staphylococcus aureus, a notorious and deadly pathogen linked to hundreds of thousands of hospitalizations each year. Their study is published online this week in Nature.
As the prescribed use of buprenorphine has dramatically increased in recent years, accidental exposure of children to the drug has risen sharply, placing them at risk for serious injury, and in extremely rare cases even death.
Drugs are currently being tested that show promise in treating patients with Duchenne muscular dystrophy (DMD), an inherited disease that affects about one in 3,600 boys and results in muscle degeneration and, eventually, death.
Pharmaceutical chemists had suggested that the objective of a drug hitting multiple targets simultaneously is impossible and unlikely to succeed. This study shows how to efficiently and effectively make designer drugs that can do that.
A two-prong approach combining ibrutinib and rituximab (Rituxin®) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center.
A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments, according to a study from researchers at the University of Michigan Comprehensive Cancer Center.
Angiocidin, a novel tumor-inhibiting protein, has shown in vitro and in vivo effectiveness against acute myeloid leukemia cells in pre-clinical experiments.
A groundbreaking clinical trial involving the breast cancer drug tamoxifen should prompt certain breast cancer patients to reconsider their treatment options.
A new drug demonstrated dramatic and rapid effects on prostate cancer that had spread to the bone, according to a study reported by University of Michigan Comprehensive Cancer Center researchers.
Phase I trial shows third-generation drug helps patients after other treatments fail.
A new drug may bring help for people with insomnia, according to a study published in the November 28, 2012, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Cedars-Sinai Heart Institute researchers have found in an initial clinical trial that a drug typically prescribed for erectile dysfunction or pulmonary hypertension restores blood flow to oxygen-starved muscles in patients with a type of muscular dystrophy that affects males, typically starting in childhood or adolescence.
In older adults, antipsychotic drugs are commonly prescribed off-label for a number of disorders outside of their Food and Drug Administration (FDA)-approved indications – schizophrenia and bipolar disorder. The largest number of antipsychotic prescriptions in older adults is for behavioral disturbances associated with dementia, some of which carry FDA warnings on prescription information for these drugs.
Researchers at the University of California, Santa Cruz, have developed a new strategy for finding novel antibiotic compounds, using a diagnostic panel of bacterial strains for screening chemical extracts from natural sources.
A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial.
Rituximab, a drug used to treat cancer and arthritis, may help patients with antiphospholipid antibodies (aPLs) who suffer from aPL-related clinical problems that do not respond to anticoagulation, according to a new study by researchers at Hospital for Special Surgery.
If you’re more of an angry, hostile type, a placebo won’t do much for you, according to a collaborative study co-authored by School of Dentistry Dean Christian Stohler.
Researchers at Moffitt Cancer Center and Duke University Medical Center have conducted a phase I trial of dasatinib, an oral SRC-family tyrosine kinase inhibitor, to determine the maximum tolerated dose when combined with paclitaxel and carboplatin to treat patients with advanced or recurrent ovarian cancer.
Researchers have developed a transgenic mouse that carries a human gene known to increase risk of Alzheimer's 15-fold. The new mouse, which mimics the genetics of the human disease more closely than any existing model, provides new evidence for the earliest cause of Alzheimer's and may prove more useful in the development of drugs to prevent or treat the disease.
Cedars-Sinai Heart Institute researchers have found that an experimental compound may help stem the debilitating effects of muscular dystrophy by restoring normal blood flow to muscles affected by the genetic disorder.
A Vanderbilt study examining the impact of the two most commonly prescribed oral diabetes medications on the risk for heart attack, stroke and death has found the drug metformin has benefits over sulfonylurea drugs.
Daily injections of liraglutide were slightly more effective than weekly injections of exenatide in lowering blood sugar and promoting weight loss. However, patients had fewer negative side effects on exenatide once weekly.
A drug therapy shows promise for treating an inherited form of kidney disease called autosomal dominant polycystic kidney disease (ADPKD), Mayo Clinic researchers say.
Elevated risk of miscarriage, preterm birth, neonatal health complications and possible longer term neurobehavioral abnormalities, including autism, suggest that a class of antidepressants known as selective serotonin reuptake inhibitors (SSRI) should only be prescribed with great caution and with full counseling for women experiencing depression and attempting to get pregnant, say researchers at Beth Israel Deaconess Medical Center, Tufts Medical Center and MetroWest Medical Center.
An oral rinse of the antidepressant doxepin significantly eased pain associated with oral mucositis in patients receiving radiation therapy for cancers of the head and neck, a study led by Mayo Clinic found. The findings were presented at the American Society for Radiation Oncology annual meeting in Boston.
Powerful antibiotics that scientists and physicians thought stop the growth of harmful bacteria by completely blocking their ability to make proteins actually allow the germs to continue producing certain proteins -- which may help do them in.
An interdisciplinary team of researchers has dissected a case of synergy in drug-resistant chronic myeloid leukemia to understand the mechanism by which two drugs, danusertib and bosutinib, work together to overcome resistance in the BCR-ABL gatekeeper mutation-specific disease. The team includes a researcher at Moffitt Cancer Center and colleagues at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in Austria and the Massachusetts Institute of Technology. The goal is to address an unmet medical need because this BCR-ABL mutation confers resistance to all currently approved kinase inhibitors for chronic myeloid leukemia.
Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results in decreasing the debilitating effects of Crohn’s Disease, according to researchers at the University of California San Diego, School of Medicine.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right